08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

Sivextro tedizolid phosphate regulatory update

EMA’s CHMP recommended approval of oral and IV Sivextro tedizolid from Merck to treat acute bacterial skin and skin structure infections (ABSSSI) in adults. CHMP said the authorization would include a pharmacovigilance plan. FDA approved...
02:16 , Jan 24, 2015 |  BC Extra  |  Company News

CHMP recommends Sivextro for ABSSSI

EMA's CHMP recommended marketing authorization of oral and IV Sivextro tedizolid from Merck & Co. Inc. (NYSE:MRK) to treat acute bacterial skin and skin structure infections (ABSSSI) in adults. CHMP said the authorization would include...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Cubist, Merck deal

Merck will acquire Cubist for $102 per share and $1.1 billion in assumption of debt in a deal valued at $9.5 billion. The cash offer of $102 per share, or $8.4 billion, represents a 37%...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Uphill road for Cubist CVRs

When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the infectious disease company owes the former shareholders of Optimer Pharmaceuticals Inc. and Trius Therapeutics...
04:04 , Dec 9, 2014 |  BC Extra  |  Top Story

Cubist: Court ruling won't upend Merck takeout

Shares of Cubist Pharmaceuticals Inc. (NASDAQ:CBST) receded slightly in after-hours trading on Monday after surging $26.24 (35%) to $100.60 on news Merck & Co. Inc. (NYSE:MRK) will acquire the biotech for $9.5 billion, including the...
02:24 , Oct 7, 2014 |  BC Extra  |  Top Story

Actavis raises stakes in ABSSSI race

Actavis plc (NYSE:ACT) will acquire Durata Therapeutics Inc. (NASDAQ:DRTX) for $675 million in cash up front, or $23 per share, plus up to $146.5 million in regulatory and commercial milestones in the form of a...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Adenium Biotech management update

Adenium Biotech ApS , Copenhagen, Denmark   Business: Infectious   Hired: Edward Fang as CMO, formerly director of clinical sciences at Trius Therapeutics Inc. , which Cubist Pharmaceuticals Inc. acquired  ...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Cubist sales and marketing update

Cubist launched an IV formulation of Sivextro tedizolid in the U.S. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). An oral formulation of...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

Cidara's antimicrobial reunion

Investors in Cidara Therapeutics Inc. 's $32 million series A round are hoping for a repeat performance by a management team with a track record of exits in the infectious disease space. 5AM Ventures led...
01:30 , Jul 1, 2014 |  BC Extra  |  Financial News

Cidara secures $32 million in series A

Cidara Therapeutics Inc. (San Diego, Calif.) secured $32 million in a series A round led by 5AM Ventures; Aisling Capital; Frazier Healthcare; and InterWest Partners. Undisclosed institutional investors also participated. Aisling's Steven Elms, Frazier's Patrick...